GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Regeneron Pharmaceuticals, Inc. (REGN) [hlAlert]

Rating:
Outperform
REGN
up 2,447.34 %

Regeneron Pharmaceuticals, Inc. (REGN) rated Outperform with price target $58 by Boenning & Scattergood

Posted on: Wednesday,  Apr 27, 2011  8:25 AM ET by Boenning & Scattergood

Boenning & Scattergood rated Outperform Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) on 04/27/2011. Previously Boenning & Scattergood rated Market Outperform Regeneron Pharmaceuticals, Inc. (NASDAQ:
REGN) on 08/26/2008., when the stock price was $21.12. Since then, Regeneron Pharmaceuticals, Inc. has gained 2447.35% as of 01/27/2016's recent price of $538.00.
If you would have followed the previous Boenning & Scattergood's recommendation on REGN, you would have gained 2447.34% of your investment in 2710 days.

Regeneron Pharmaceuticals Inc. is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic drugs for thetreatment of serious medical conditions. Regeneron's platform technologies include Targeted GenomicsTM, FunctionomicsTM, and Designer Protein TherapeuticsTM. Regeneron has drugs in clinical and preclinical development for the potential treatment of obesity, rheumatoid arthritis, cancer, allergies, asthma, amyotrophic lateral sclerosis, constipating conditions, ischemia, and other diseases and disorders. (PRESS RELEASE)

Our equity research team concentrates on companies that aren’t widely covered in sectors such as water distribution/equipment/technology, financial services, business services, aerospace & defense technology, medical technology and retail.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
4/27/2011 8:25 AM Buy
None
55.34 58.00
as of 12/30/2011
1 Week down  -0.25 %
1 Month down  -6.71 %
3 Months down  -4.75 %
1 YTD up  68.83 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
8/26/2008 8:25 AM Buy
None
21.12

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy